权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Dual Role of Lysyl Oxidase in Arteriovenous Fistula Failure

赖氨酰氧化酶在动静脉内瘘衰竭中的双重作用

基本信息

批准号：
10190926
负责人：
YAN-TING E. SHIU
金额：
$ 37.93万
依托单位：
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-17 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10190926
关键词：
Animal Model Animals Area Arteries Arteriovenous fistula Attenuated Biological Biomechanics Blood Vessels Blood flow Catheters Cell Nucleus Cells ChIP-seq Collagen Complex Complication Copper Data Docking Elastin End stage renal failure Enzymes Epigenetic Process Experimental Animal Model Experimental Models Extracellular Protein Extracellular Space Failure Family suidae Fibrosis Fistula Functional disorder Gene Expression Genes Genetic Transcription Goals Hemodialysis Histone Code Histone H3 Histones Human Hyperplasia In Situ In Vitro Intervention Knockout Mice Limb structure Location Lysine Maintenance Manuscripts Mass Spectrum Analysis Medial Mediating Medical Microscopy Modeling Morbidity - disease rate Mus Myography Nuclear Nucleosomes Operative Surgical Procedures Outcome Study Pathogenicity Patients Pharmacology Phenotype Postoperative Period Pre-Clinical Model Procedures Protein-Lysine 6-Oxidase Publishing Quality of life Research Risk Role Safety Secure Site Smooth Muscle Myocytes Source Stenosis Techniques Testing Thick Thrombosis Time Up-Regulation Veins Venous amine oxidase arm biobank cell type cohort conditional knockout cost crosslink design histone modification improved inhibitor/antagonist medical complication mortality myocardin nanofiber neointima formation new therapeutic target novel novel therapeutic intervention novel therapeutics pre-clinical preservation prevent promoter protein crosslink scaffold transcriptome sequencing transcriptomics

项目摘要

The failure of hemodialysis arteriovenous (A-V) fistulas, which are surgically created by anastomosing a vein to a nearby artery, remains an unmet medical problem in the field of vascular surgery. In fact, approximately four out of 10 newly created fistulas will require a surgical or intravascular salvage procedure to reach maturation and become suitable for hemodialysis. Arteriovenous fistulas fail because stenosis (vascular narrowing) prevents high blood flows through the venous limb and increases the risk for thrombosis. We recently discovered that stenosis occurs due to excessive medial fibrosis and increased extracellular protein crosslinking, and is aggravated by intimal hyperplasia (IH) in a human cohort of 165 patients. Therefore, our overall goals are, first, to establish the cause-and-effect relationship between LOX, the most important enzyme responsible for crosslinking, and A-V fistula failure and, second, to design new therapeutics to facilitate A-V fistula maturation through perivascular delivery of LOX inhibitors. Our proposal is built on strong scientific premises (manuscripts and unique preliminary data) that suggest a mechanistic relationship between postoperative upregulation of LOX in native fistulas and the improper wall remodeling that causes fistula failure. Specifically, our overarching hypothesis is that LOX activity is a major contributor in A-V fistula maturation failure. Our primary hypothesis is that postsurgical upregulation of nuclear LOX deaminates lysine residues in histones to disrupt the epigenetic landscape that secures contractile gene expression in SMCs, thereby facilitating their maladaptive phenotypic switch, neointima formation, and fibrosis of newly created A-V fistulas. Our secondary hypothesis is that inhibition of LOX prevents inward remodeling in a preclinical A-V fistula model in swine. We will test our hypothesis in three specific aims that will: 1) identify the cellular source of LOX after A-V fistula creation, 2) demonstrate the impact of LOX mediated histone modifications on the SMC phenotype after fistula creation, and 3) demonstrate that LOX inhibitors attenuate inward remodeling, IH, and stenosis in preclinical A-V fistulas in swine. We will use fine microsurgical techniques in novel conditional knockout mice and in vitro and in situ models to successfully achieve our goals. We will also use a preclinical model in swine to demonstrate the efficacy and safety of perivascular delivery of LOX inhibitors in preventing A-V fistula failure. In conclusion, with the successful accomplishment of this proposal, we are paving the way for the design of new drugs and cell type-specific interventions to effectively target A-V fistula fibrosis and reduce vascular access complications.

血液透析动静脉（A-V）瘘的失败，这是由手术造成的